{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:26:53Z","timestamp":1772166413021,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T00:00:00Z","timestamp":1592784000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T00:00:00Z","timestamp":1592784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Science and Technology Major Project of China during the 13th Five-year plan period","award":["2018ZX10302104"],"award-info":[{"award-number":["2018ZX10302104"]}]},{"DOI":"10.13039\/501100011930","name":"Beijing Medical and Health Foundation","doi-asserted-by":"publisher","award":["YWJKJJHKYJJ-TM19001"],"award-info":[{"award-number":["YWJKJJHKYJJ-TM19001"]}],"id":[{"id":"10.13039\/501100011930","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      <jats:italic>Pneumocystis<\/jats:italic>\n                      pneumonia (PCP) is a common acquired immune deficiency syndrome (AIDS)-related opportunistic infection. Recent reports estimate that more than 400,000 patients with human immunodeficiency virus (HIV) develop PCP each year globally. However, the timing of antiretroviral therapy (ART) initiation for HIV-infected patients with PCP is still controversial, and the benefits and risks of early initiation of ART are not completely clear. We thus designed this study in order to determine the optimal timing for ART initiation for HIV-positive patients with moderate to severe PCP.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study will be an open-label, multi-centre, prospective randomised controlled trial. A total of 200 subjects will be randomly assigned to an early ART initiation group (\u226414\u2009days after PCP diagnosis) and a deferred ART initiation group (&gt;14\u2009days after PCP diagnosis) at a 1:1 ratio. All subjects will be followed up for 48\u2009weeks after starting ART. The primary endpoint is incidence of disease progression (including new or relapsing opportunistic infections and death) at week 48. The secondary endpoints are the changes in CD4 counts from baseline at weeks 12, 24 and 48; the degree of virological suppression (HIV RNA\u2009&lt;\u200950 copies\/mL) at weeks 24 and 48; the rate of development of PCP-associated immune reconstitution inflammatory syndrome; and adverse events over 48\u2009weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>We hope that the results of this study will reveal the optimal timing for initiation of ART in HIV-infected patients with moderate to severe PCP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      This trial was registered as one of the 12 trials under the name of a general project at\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/chictr.org.cn\">chictr.org.cn<\/jats:ext-link>\n                      on February 1, 2019. The registration number of the general project is\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.chictr.org.cn\/showproj.aspx?proj=35362\">ChiCTR1900021195<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-020-04450-8","type":"journal-article","created":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T06:02:55Z","timestamp":1592805775000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Timing of antiretroviral therapy for HIV-infected patients with moderate to severe Pneumocystis pneumonia: study protocol for a multi-centre prospective randomised controlled trial"],"prefix":"10.1186","volume":"21","author":[{"given":"Yuanyuan","family":"Qin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanqiu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yihong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay","family":"Harypursat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengquan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqing","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanming","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaokai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,22]]},"reference":[{"issue":"12","key":"4450_CR1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000681","volume":"94","author":"C Lopez-Sanchez","year":"2015","unstructured":"Lopez-Sanchez C, Falco V, Burgos J, Navarro J, Martin MT, Curran A, et al. Epidemiology and long-term survival in HIV-infected patients with Pneumocystis jirovecii pneumonia in the HAART era: experience in a university hospital and review of the literature. Medicine (Baltimore). 2015;94(12):e681.","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"4450_CR2","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.tim.2014.01.001","volume":"22","author":"D Armstrong-James","year":"2014","unstructured":"Armstrong-James D, Meintjes G, Brown GD. A neglected epidemic: fungal infections in HIV\/AIDS. Trends Microbiol. 2014;22(3):120\u20137.","journal-title":"Trends Microbiol"},{"key":"4450_CR3","doi-asserted-by":"crossref","unstructured":"Bongomin F, Gago S, Oladele RO, Denning DW. Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision. J Fungi (Basel). 2017;3(4):57.","DOI":"10.3390\/jof3040057"},{"issue":"11","key":"4450_CR4","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1016\/S1473-3099(17)30303-1","volume":"17","author":"AH Limper","year":"2017","unstructured":"Limper AH, Adenis A, Le T, Harrison TS. Fungal infections in HIV\/AIDS. Lancet Infect Dis. 2017;17(11):e334\u201343.","journal-title":"Lancet Infect Dis"},{"issue":"24","key":"4450_CR5","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMra032588","volume":"350","author":"CF Thomas Jr","year":"2004","unstructured":"Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N Engl J Med. 2004;350(24):2487\u201398.","journal-title":"N Engl J Med"},{"issue":"4","key":"4450_CR6","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrmicro1621","volume":"5","author":"CF Thomas Jr","year":"2007","unstructured":"Thomas CF Jr, Limper AH. Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nat Rev Microbiol. 2007;5(4):298\u2013308.","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"4450_CR7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12981-019-0250-2","volume":"16","author":"G Schafer","year":"2019","unstructured":"Schafer G, Hoffmann C, Arasteh K, Schurmann D, Stephan C, Jensen B, et al. Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (toxoplasmosis, Pneumocystis jirovecii-pneumonia): a prospective, randomised, open-label multicenter study (IDEAL-study). AIDS Res Ther. 2019;16(1):34.","journal-title":"AIDS Res Ther"},{"issue":"5","key":"4450_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0005575","volume":"4","author":"A Zolopa","year":"2009","unstructured":"Zolopa A, Andersen J, Powderly W, Sanchez A, Sanne I, Suckow C, et al. Early antiretroviral therapy reduces AIDS progression\/death in individuals with acute opportunistic infections: a multicenter randomised strategy trial. PLoS One. 2009;4(5):e5575.","journal-title":"PLoS One"},{"key":"4450_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e7586","volume":"346","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.","journal-title":"BMJ"},{"issue":"12","key":"4450_CR10","first-page":"867","volume":"57","author":"AIDS and Hepatitis C Professional Group","year":"2018","unstructured":"AIDS and Hepatitis C Professional Group. Society of Infectious Diseases, Chinese Medical Association, Chinese Center for Disease Control and Prevention: Chinese guidelines for diagnosis and treatment of HIV\/AIDS (2018). Zhonghua nei ke za zhi. 2018;57(12):867\u201384.","journal-title":"Zhonghua nei ke za zhi"},{"key":"4450_CR11","unstructured":"Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS, Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-infected Adults and Adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. 2020. http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adult_oi.pdf. Accessed 10 Jan 2020."},{"key":"4450_CR12","unstructured":"Medical Research Platform. http:\/\/www.51yyt.org\/FrontPage\/login.aspx?Inviter=. Accessed 10 May 2020."},{"key":"4450_CR13","unstructured":"U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1. 2017. https:\/\/rsc.niaid.nih.gov\/sites\/default\/files\/daidsgradingcorrectedv21.pdf. Accessed 17 May 2020."},{"key":"4450_CR14","unstructured":"U.S. Food and Drug Administration. What is a Serious Adverse Event? 2016. https:\/\/www.fda.gov\/safety\/reporting-serious-problems-fda\/what-serious-adverse-event. Accessed 17 May 2020."},{"issue":"2","key":"4450_CR15","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/jac\/dki444","volume":"57","author":"SA Shelburne","year":"2006","unstructured":"Shelburne SA, Montes M, Hamill RJ. Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemother. 2006;57(2):167\u201370.","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"4450_CR16","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1086\/593194","volume":"47","author":"N Longley","year":"2008","unstructured":"Longley N, Muzoora C, Taseera K, Mwesigye J, Rwebembera J, Chakera A, et al. Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. Clin Infect Dis. 2008;47(12):1556\u201361.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"4450_CR17","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1111\/j.1469-0691.2012.03991.x","volume":"19","author":"C Manzardo","year":"2013","unstructured":"Manzardo C, Esteve A, Ortega N, Podzamczer D, Murillas J, Segura F, et al. Optimal timing for initiation of highly active antiretroviral therapy in treatment-naive human immunodeficiency virus-1-infected individuals presenting with AIDS-defining diseases: the experience of the PISCIS Cohort. Clin Microbiol Infect. 2013;19(7):646\u201353.","journal-title":"Clin Microbiol Infect"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-020-04450-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-020-04450-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-020-04450-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T19:46:14Z","timestamp":1624304774000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-020-04450-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,22]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4450"],"URL":"https:\/\/doi.org\/10.1186\/s13063-020-04450-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-19306\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,22]]},"assertion":[{"value":"26 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We submitted the ethical review materials for this study to the ethics committee for the first time on January 17, 2019. After submission of the \u201cReview Application\u201d for the revised document according to the review opinion, this study was approved by the ethics committee of the Chongqing Public Health Medical Center (2019\u2013003-02-KY) on January 28, 2019, and this approval covered local approval within other research centres. Confirmation of capacity and capability was also carried out by each local centre. Ethics approval documents and subsequent updated versions were filed at the local ethics committee. Written informed consent will be obtained from each patient before randomisation. All subjects will be requested to sign an informed consent form before enrolment in the study. If there are any changes to the protocol, the sponsor and the funder will be informed initially and then the principal investigator will notify the centres and will save a copy of the revised protocol in the investigator site file. Any deviations from the protocol will be fully documented using a breach report form. The information in the clinical trial registry will be updated according to the revised protocol. On the consent form, participants will be asked whether they agree to the use of their data should they choose to withdraw from the trial. Participants will also be asked for permission for the research team to share relevant data with the universities taking part in the research or from regulatory authorities, where relevant. This trial collects biological specimens for storage. There is no anticipated harm and compensation for trial participation, and there will be no further provision for post-trial care. Consent forms are available from the corresponding author on request.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"551"}}